期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

MicroRNA在三阴性乳腺癌发生发展中的作用 被引量：3

Progression on the role of microRNAs in the initiation and progression of triple negative breast cancer
下载PDF
导出
摘要 microRNA(miRNA)是近年来发现的一种可以调控基因表达的单链小分子RNA,其表达异常或突变被认为与多种肿瘤的发生、发展有关。有研究表明,miRNA在三阴性乳腺癌中扮演着重要角色,这将为后者的治疗提供新思路。本文就miRNA作为一种新的分子标志物在三阴性乳腺癌中的研究进展作一综述。 MicroRNAs （ miRNAs） are recently discovered, small single-strand RNA molecules that can regulate gene expres-sion, and the abnormal expression or mutation in miRNAs are considered to be associated with the initiation and progression of a variety of tumors. It has been identified that miRNAs play a crucial role in triple negative breast cancer, providing a novel possible therapeutic application. In this review, we will provide an overview of the application of miRNAs in triple negative breast cancer.
作者 杨芳 管晓翔
机构地区 南京大学医学院临床学院南京军区南京总医院肿瘤内科
出处 《临床肿瘤学杂志》 CAS 2014年第10期950-952,共3页 Chinese Clinical Oncology
基金 国家自然科学基金资助项目(81272252) 江苏省自然科学基金资助项目(BK2011656)
关键词 MIRNA 三阴性乳腺癌 分子标志物 miRNA Triple negative breast cancer Biomarker
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献25

  • 1Leclercq M, Diallo AB, Blanchette M. Computational prediction of the localization of micromas within their pre-mirna[J]. Nucleic Acids Res, 2013, 41 (15): 7200-7211.
  • 2Hausser J, Syed AP, Bilen B, et al. Analysis of cds-located mirna target sites suggests that they can effectively inhibit transla- tion[J]. Genome Res, 2013, 23 (4) : 604-615.
  • 3Riaz M, van Jaarsveld MT, Hollestelle A, et al. Mima expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific mimas [ J ]. Breast Cancer Res, 2013, 15 (2) : R33.
  • 4Janssen EA, Slewa A, Gudlaugsson E, ct al. Biologic profiling of lymph node negative breast cancers by means of microrna expres- sion[J]. Mod Pathol, 2010, 23 (12): 1567-1576.
  • 5Cascione L, Gasparini P, Lovat F, et al. Integrated microrna and mrna signatures associated with survival in triple negative breast cancer[ J/OL ]. PLoS One, 2013 [ 2014-05-06 ]. http://www. ncbi.nlm.nih, gov/pmc/articles/PMC3566108.
  • 6魏清筠,朱远源,彭薇,王旻.MicroRNA在肿瘤诊断、治疗中的应用[J].现代生物医学进展,2011,11(19):3794-3797. 被引量：2
  • 7Wang J, Zhao H, Tang D, et al. Overexpressions of microrna-9 and microrna-200c in human breast cancers are associated with lymph node metastasis [ J/OL ]. Cancer Biother Radiopharm, 201312014-05-06]. http ://www. ncbi. nlm. nih. gov/pubmed/23- 617747.
  • 8Blick T, Hugo H, Widodo E, et al. Epithelial mesenchymal tran- sition traits in human breast cancer cell lines parallel the cd44 (hi/) cd24 (lo/-) stem cell phenotype in human breast cancer [J]. J Mammary Gland Biol Neoplasia, 2010, 15 (2): 235 -252.
  • 9Ahmad A, Aboukameel A, Kong D, et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelial- mesenchymal transition regulated by mir-200 in breast cancer cells [J]. Cancer Res, 2011, 71 (9) : 3400-3409.
  • 10Elson-Schwab I, Lorentzen A, Marshall CJ. Microrna-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion [ J/OL]. PLoS One, 2010 [ 2014-05- 06]. http ://www. nebi. nlm. nih. gov/pmc/artieles/PMC2949394.

二级参考文献25

  • 1Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers[J]. Nature, 2005, 435(7043): 834-838.
  • 2Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis [J]. Cancer Cell, 2006, 9(3): 189-198.
  • 3Heneghan HM, Miller N, Kerin MJ. MiRNAs as biomarkers and therapeutic targets in cancer [J]. Curr Opin Pharmacol, 2010, 10 (5): 543-550.
  • 4Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patiens with diffuse large B-cell lymphoma[J]. BrJ Haematol, 2008, 141(5): 672-675.
  • 5Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer, a potential marker for colorectal cancer screening[J]. Gut, 2009, 58(10): 1375-1381.
  • 6Li C, Feng Y, Coukos G, et al, Therapeutic microRNA strategies in human cancer[l]. AAPS J, 2009, 11(4): 747-757.
  • 7Weiler J, Hunzlker J, Hall J. Anti-mi_KNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease[J]? Gene Ther, 2006, 13(6): 496-502.
  • 8Yang ZY, Vilkaitis G, Yu B, et al. Approaches for studying MicroRNA and small interfering RNA methylation in vitro and in vivo [J]. Methods Enzymol, 2007, 427:139-154.
  • 9Orom UA, Kauppinen S, Lurid AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function[J]. Gene, 2006, 10 (372): 137-141.
  • 10Si ML, Zhu S, WuH, et al. miR-21-mediated tumor growth[J]. Oncogene, 2007, 26(19): 2799-2803.

共引文献1

同被引文献42

  • 1Meena M.Radiation therapy in the locoregional treatment of triple-negative breast cancer[J].Lancet Oncol,2015,16(3):113-122.
  • 2Boyle P.Triple-negative breast cancer:epidemiological considerations and recommendations[J].Ann Oncol,2012,23(6):7-12.
  • 3Sioshansi S,Ehdaivand S,Cramer C,et al.Triple negative breast cancer is associated with an increased risk of residual invasive carcinoma after lumpectomy[J].Cancer,2012,118(16):3893-3898.
  • 4Part A,Adamo B,Cheang MC,et al.Molecular characterization of basal-like and non-basal-like triple-negative berast cancer[J].Oncologist,2013,18(2):123-133.
  • 5Lehmann BD,Bauer JA,Chen X,et al.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J].J Clin Invest,2011,121(7):2750-2767.
  • 6Lehmann BD,Pietenpol JA.Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes[J].J Pathol,2014,232(2):142-150.
  • 7Lehmann BD,Bauer JA,Chen X,et al.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest,2011,121(7):2750-2767.
  • 8Gazinska P,Grigoriadis A,Brown JP,et al.Comparison of basal-like triple-negative breast cancer defined by morphology,immunohistochemistry and transcriptional profiles[J].Mod Pathol,2013,26(7):955-966.
  • 9Perou CM.Molecular stratification of triple-negative breast cancers[J].Oncologist,2010,15(5):39-48.
  • 10Kyndi M,Srensen FB,Knudsen H,et al.Estrogen receptor,progesterone receptor,HER-2,and response to postmastectomy radiotherapy in high-risk breast cancer:the Danish Breast Cancer Cooperative Group[J].Clin Oncol,2008,26(9):1419-1426.

引证文献3

二级引证文献4

临床肿瘤学杂志
2014年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部